About Allozyne
Allozyne is a company based in Seattle (United States) founded in 2005 by Dee Datta and William Goddard was acquired by MedImmune in September 2014. Allozyne has raised $40.46 million across 6 funding rounds from investors including ARE, Arch Venture Partners and MedImmune. The company has 6 employees as of December 31, 2017. Allozyne operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Seattle, United States
- Employees 6 as on 31 Dec, 2017
- Founders Dee Datta, William Goddard
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Allozyne, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Allozyne
Allozyne has successfully raised a total of $40.46M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $2.45 million completed in August 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Allozyne
Allozyne has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, Arch Venture Partners and MedImmune.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
Early-stage VC investments are focused primarily on US companies.
|
Locked | Locked | Locked | |
|
Venture capital investments are facilitated by Amgen-backed entity.
|
Locked | Locked | Locked |
Investor details for Allozyne
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Allozyne
Investment portfolio details for Allozyne
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Allozyne
Detailed financials for Allozyne
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Allozyne Comparisons
Peer comparison for Allozyne
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Allozyne
Allozyne operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
Detailed competitors of Allozyne
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Allozyne
Complete news archive for Allozyne
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Allozyne
Allozyne was founded in 2005.
Allozyne is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Allozyne is a funded company, having raised a total of $40.46M across 6 funding rounds to date.
As of Dec 31, 2017, the latest employee count at Allozyne is 6.
Allozyne was founded in 2005 in Seattle, United States, within the biotechnology sector. Technologies are developed and commercialized to enhance efficacy, safety, and dosing of protein-based therapeutics, including peptides, antibodies, and vaccines. A PEGylated IFN beta product was created for multiple sclerosis treatment. Platforms enable amino acid analogue incorporation for improved biologics and next-generation antibody-drug conjugates. The company was acquired by MedImmune in 2014.
Allozyne's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Allozyne has 7 investors. Key investors include ARE, Arch Venture Partners, MedImmune, Turmeric Acquisition Corp, and OVP Venture Partners.